



PATENT
Customer No. 22,852
Attorney Docket No. 02481.1215-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Robert Ryder Bartlett et al.) Prior Group Art Unit: 1617
)
Continuation of) Prior Examiner: T. Criares
Application No.: 09/189,866)
)
Filed: Filed Herewith)
)
For: PHARMACEUTICALS FOR THE)
TREATMENT OF REJECTION)
REACTIONS IN ORGAN)
TRANSPLANTATIONS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed together with this continuation application.

Copies of most listed documents were previously made of record in parent application no. 09/189,866, filed on November 12, 1998, upon which applicants rely for the benefits provided in 35 U.S.C. § 120. Copies the remaining listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

The following applies to the non-English language documents:

DE 3534440: A Derwent Abstract of this document is attached.

DE 4101324: A Derwent Abstract of this document is attached.

EP 013 376: This document contains English language claims.

EP 0 217 206: This document contains English language claims.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited document do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 25, 2003


By: _____


Steven J. Scott
Reg. No. 43,911

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Docket No.	02481.1215-04	Appln. No.	Unassigned
Applicant	Robert Ryder Bartlett		
Filing Date	Filed herewith	Group:	Unassigned



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	4,061,761	12/77	Ertel et al.			
	4,965,276	10/90	Bartlett et al.			
	4,284,786	08/81	Kammerer et al.			
	4,087,535	05/78	Heubach			
	4,284,786	08/81	Kammerer et al.			
	4,351,841	09/82	Kammerer et al.			
	4,636,513	01/87	Kammerer et al.			
	5,268,382	12/93	Bartlett et al.			
	5,100,899	03/92	Caine			
	5,624,946	04/97	Williams			
	6,288,098	09/01	Bartlett			
	5,688,824	11/97	Williams			
	5,728,721	03/98	Bartlett			
	6,133,301	10/00	Bartlett			

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
DE 3534440A1	04/87	Germany			No
EP 013 376 B1	7/80	Europe			No
EP 0 217 206	4/87	Europe			No
2076555	2/93	Canada			No
2081173	4/93	Canada			No
4101324A1	7/92	Germany			No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Auchincloss, Jr., "Xenogeneic Transplantations", Transplantation, 46(1):1-20.
Ivan M. Roitt et al., "Immunology", ch. 24 "Transplantation and Rejection", pp. 24.1 to 24.9, Gower Medical Publishing (1985).

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1215-04	Appln. No.	Unassigned
Applicant	Robert Ryder Bartlett		
Filing Date	Filed herewith	Group:	Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	K. Ulrichs et al., "Suppression of Natural Xenophile Antibodies with the Novel Immunomodulating Drug Leflunomide," Transplantation Proceedings, Vol. 24, No. 2 (April 1992), pp. 718-719.
	C.C.A. Kuchle et al., "Prevention of Kidney and Skin Graft Rejection Rates by Leflunomide, a New Immunomodulating Agent," Transplantation Proceedings, Vol. 23, No. 1 (February 1991), pp. 1083-1086.
	D.B.J. Herrmann et al., "Drugs in Autoimmune Diseases," Klinische Wochenschrift, Vol. 68 (Suppl. XXI)(1990), pp. 15-25.
	Bartlett et al., "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection," Agents Actions, Vol. 32, Nos. ½, 32:10-21 (1991).
	Bartlett et al., "Development of Autoimmunity in MRL/lpr Mice and the Effects of Drugs on this Murine Disease," Scand. J. Rheumatology, S75:290-299 (1988).
	Bretzel et al., "Experimental Islet Transplantation in Small Animals," Pancreatic Islet Cell Transplantation, C. Ricardi, e., R.G. Landis Co., Austin, TX (1992).
	Chong et al., "Leflunomide, a Novel Immunomodulatory Agent: In Vitro Analyses of the Mechanism of Immunosuppression," Transplantation Proceedings, 25:747-749 (1993).
	Chong et al., "Leflunomide, a Novel Immunosuppressive Agent," Transplantation, 55:1361-1366 (1993).
	Cosenza et al., "Combination Therapy with Brequinar Sodium and Cyclosporine Synergistically Prolongs Hamster-to-Rat Cardiac Xenograft Survival," J. Heart Lung Transplantation, 13:489-497 (1994).
	Fontana et al., "Long-Term Follow-Up of Human Islet Autotransplantation," Transplantation Proceedings, 26:581 (1994).
	Foster et al., "Leflunomide Immunosuppression in Rat Small Intestinal Transplantation," Transplantation Proceedings, 26:1599-1600 (1994).
	Glant et al., "Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide," Immunopharmacology, 23:105-116 (1992).
	Hayry et al., "Chronic Allograft Rejection," Immunological Reviews, 134:33-81 (1993).
	Horak et al., "T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56 ^{lck} ," Proc. Natl. Acad. Sci. USA, 88:1996-2000 (1991).
	Kahan et al., "Synergistic Interactions of Cyclosporine and Rapamycin to Inhibit Immune Performances of Normal Human peripheral Blood Lymphocytes In Vitro," Transplantation, 51:232-239 (1991).
	Kerckhaert et al., "Effects of Variation in Time and Dose of Cyclophosphamide Injection on Delayed Hypersensitivity and Antibody Formation," Cellular Immunology, 29:232-237 (1977).
	Küchle et al., "Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immunomodulating Agent," Transplantation Proceedings, 23:1083-1086 (1991).

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1215-04	Appln. No.	Unassigned
Applicant	Robert Ryder Bartlett		
Filing Date	Filed herewith	Group:	Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Mattar et al., "Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide," FEBS Letters, 334:161-164 (1993).
	McChesney et al., "An Evaluation of Leflunomide in the Canine Renal Transplantation Model," Transplantation, 57:1717-1722 (1994).
	Ogawa et al., "Effects of Leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats," Agents Actions, 31:321-328 (1990)
	Ogawa et al., "Therapeutic Effects of Leflunomide, a New Antirheumatic Drug, on Glomerulonephritis Induced by the Antibasement Membrane Antibody in Rats," Clinical Immunology Immunopathology, 61:103-118 (1991).
	Ono et al., "Improved technique of heart transplantation in rats," J. Thoracic Cardiovascular Surgery, 57:225-229 (1969).
	Popovic et al., "Disease modifying activity of HWA 496 on the development of SLE in MRL/1-mice," Agents Actions, 19:313-314 (1986).
	Schorlemmer et al., "Prolongation of Allogenic Transplanted Skin Grafts and Induction of Tolerance by Leflunomide, a New Immunosuppressive Isoxazol Derivative," Transplantation Proceedings, 25:763-767 (1993).
	Schwartz et al., "Drug-Induced Immunological Tolerance," Nature, 183:1682-1683 (1959).
	Stecher et al., "Disease Modifying Anti-Pneumatic Drugs," Ann. Report Med. Chem. 18:171-179 (1983).
	Stockman et al., "Differential Effects of cyclophosphamide on the B and T Cell Compartments of Adult Mice," J. Immunology, 110:227-282 (1973).
	Thoenes et al., "Leflunomide (HWA 486) Inhibits Experimental Autoimmune Tubulointerstitial Nephritis in Rats," Int. J. Immunopharmacology, 11:921-929 (1989).
	Tiney et al., "Chronic Rejection - An Undefined Conundrum", Transplantation, 52:389-398 (1991).
	Turk et al., "Further Studies on B-Lymphocyte Suppression in Delayed Hypersensitivity, Indicating a Possible Mechanism for Jones-Mote Hypersensitivity," 24:751-758 (1973).
	Williams et al., "Leflunomide Based Immunosuppression in Rat Cardiac and Renal Xenotransplantation," Presented at Annual Meeting of the Am. Soc. Transplant Surgeons, May 20, 1994, Chicago, IL.
	Williams et al., "Leflunomide and Cyclosporin in Rat Cardiac Transplantation", Presented at Annual Meeting of the Am. Soc. Transplant Surgeons, May 1992, Chicago, IL.
	Williams et al., "Leflunomide in Experimental Transplantation," Transplantation, 57:1223-1231 (1994).
	Xiao et al., "Effect of Leflunomide in Control of Acute Rejection in Hamster-to-Rat Cardiac Xenografts," Transplantation Proceedings, 26:1263-1264 (1994).


INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1215-04	Appln. No.	Unassigned
Applicant	Robert Ryder Bartlett		
Filing Date	Filed herewith	Group:	Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Bouwan et al., "Experimental Xenotransplantation in Rodents -- I: Skin Versus Heart Grafts," in Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 323-329.
	Cooper et al., "Introduction," in Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 1-7.
	Steinbruch et al., "Experimental Xenotransplantation in Rodents-Total Lymphoid Irradiation, Cyclosporine, and Monoclonal Antibodies," Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 331-338.
	Thomas et al., "Immunobiology of Xenografting in Rodents," in Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 139-160.
	Van Den Bogaerde et al., "Immunosuppression in Xenotransplantation," in Xenotransplantation, Cooper et al., eds. Springer-Verlag, Berlin (1991), pp. 161-178.
	Ricordi et al., "Islet Isolation Assessment," Pancreatic Islet Cell Transplantation, Camillio Ricordi, ed. RG Landis Co., Austin, TX pp. 132-142 (1992).
	Williams et al., "Leflunomide, A Potent Immunosuppressive Molecule," International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, Switzerland (Feb. 10, 1994).
	London et al., "Islet Purification," Pancreatic Islet Cell Transplantation, Camillio Ricordi, ed; RG Landis, Co., Austin, TX, pp. 113-123 (1992).
	Farney et al., "Islet Autotransplantation: The Minnesota Experience," Pancreatic Islet Cell Transplantation, C. Richardi, ed., R.G. Landis Co., Austin, TX (1992), pp. 291-312.
	Williams et al., "Immunosuppressive Effects of Leflunomide in a Cardiac Allograft Model," Transplantation Proceedings, 25:745-746 (1993).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

Application Number 	Application/Control No. 10/626,600	Applicant(s)/Patent under Reexamination BARTLETT, ROBERT RYDER	
Document Code - DISQ	Internal Document – DO NOT MAIL		

TERMINAL DISCLAIMER	<input checked="" type="checkbox"/> APPROVED	<input type="checkbox"/> DISAPPROVED
Date Filed : 15 DEC 2006	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:
JAB PN 6,133,301.